Nan Cao
Research Subjects
Nan Cao has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Aibing Xu
13Department of Invasive Technology, Nantong Tumor Hospital, Nantong, China
9 shared publications - Chongyuan Xu
10Department of Infectious Medicine Liver Cancer Center, Nanfang Hospital of Southern Medical University, Guangzhou, China
9 shared publications - Di Yang
14Harbour BioMed, Shanghai, China
9 shared publications - Fei Zheng
14Harbour BioMed, Shanghai, China
9 shared publications - Gang Wang
Department of Hepatobiliary Pancreatic and Splenic Surgery, Baoji Central Hospital, Baoji, China
9 shared publications - Ge Yu
Department of Hepatobiliary and Pancreatic Medicine, The First Bethune Hospital of Jilin University, Changchun, China
9 shared publications
Latest Publications
- Open Access
- 1 March 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-13
Safety, Tolerability, and Pharmacokinetics of HBM9378 (SKB378/WIN378), a Fully Human IgG1 Monoclonal Antibody Against TSLP After Single Ascending Doses in Chinese Healthy Subjects
HBM9378 (SKB378/WIN378) is a novel monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), characterized by an extended half-life and developed to address the unmet medical need for a more durable and convenient biologic therapy for asthma. This first-in-human (FIH) study was conducted to evaluate the safety, tolerability, pharmacokinetics (PK) and immunogenicity of HBM9378 in healthy subjects, providing essential human data to support further clinical development. This Phase I study utilized a single ascending dose (SAD) design with randomization, double-blinding, and placebo control. Five dose-escalation cohorts were included: 20 mg, 60 mg, 200 mg, 600 mg, and 900 mg. Each cohort comprised ten healthy subjects, of whom eight received HBM9378 at the assigned dose and two received placebo. Safety was evaluated through monitoring of adverse events and laboratory assessments. Pharmacokinetics (PK) were characterized by calculating and comparison of key PK parameters. Immunogenicity was assessed by determining the incidence of anti-drug antibody (ADA) following administration. The safety profiles of the HBM9378 dose groups were comparable to those of the placebo group with respect to treatment-emergent adverse events (TEAEs), and no dose-dependent increase in safety risk was observed. The median Tmax was 4.05–14.1 days and the mean T1/2 was 55.0–65.8 days. HBM9378 exposure (Cmax and AUC) increased dose-proportionally across the 20–900 mg dose range, and the ADA incidence during the study was 5% (2/40). HBM9378 was well-tolerated and exhibited a prolonged half-life in healthy subjects. These results support further investigation of HBM9378 in patients with severe immunological disorders. This trial was registered on ClinicalTrials.gov (NCT05790694) and on the China Center for Drug Evaluation (CDE) platform (CTR20221961).
- 1 March 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-13
Open AccessSafety, Tolerability, and Pharmacokinetics of HBM9378 (SKB378/WIN378), a Fully Human IgG1 Monoclonal Antibody Against TSLP After Single Ascending Doses in Chinese Healthy Subjects
HBM9378 (SKB378/WIN378) is a novel monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), characterized by an extended half-life and developed to address the unmet medical need for a more durable and convenient biologic therapy for asthma. This first-in-human (FIH) study was conducted to evaluate the safety, tolerability, pharmacokinetics (PK) and immunogenicity of HBM9378 in healthy subjects, providing essential human data to support further clinical development. This Phase I study utilized a single ascending dose (SAD) design with randomization, double-blinding, and placebo control. Five dose-escalation cohorts were included: 20 mg, 60 mg, 200 mg, 600 mg, and 900 mg. Each cohort comprised ten healthy subjects, of whom eight received HBM9378 at the assigned dose and two received placebo. Safety was evaluated through monitoring of adverse events and laboratory assessments. Pharmacokinetics (PK) were characterized by calculating and comparison of key PK parameters. Immunogenicity was assessed by determining the incidence of anti-drug antibody (ADA) following administration. The safety profiles of the HBM9378 dose groups were comparable to those of the placebo group with respect to treatment-emergent adverse events (TEAEs), and no dose-dependent increase in safety risk was observed. The median Tmax was 4.05–14.1 days and the mean T1/2 was 55.0–65.8 days. HBM9378 exposure (Cmax and AUC) increased dose-proportionally across the 20–900 mg dose range, and the ADA incidence during the study was 5% (2/40). HBM9378 was well-tolerated and exhibited a prolonged half-life in healthy subjects. These results support further investigation of HBM9378 in patients with severe immunological disorders. This trial was registered on ClinicalTrials.gov (NCT05790694) and on the China Center for Drug Evaluation (CDE) platform (CTR20221961).
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Supplementary Table S1. Representativeness of Study Participants.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Supplementary Table S1. Representativeness of Study Participants.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Supplementary Figure S4. The PFS and OS curves.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Supplementary Figure S4. The PFS and OS curves.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Supplementary Figure S3. Exploration of the association between the tumor immune microenvironment and efficacy.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Supplementary Figure S3. Exploration of the association between the tumor immune microenvironment and efficacy.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Supplementary Figure S1. Patients enrollment flowchart.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Supplementary Figure S1. Patients enrollment flowchart.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Supplementary Table S2. Safety data.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Supplementary Table S2. Safety data.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Supplementary Table S3. Density of various immune cells and their ratio to CD8+ cells as revealed by multiplex immunofluorescence.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Supplementary Table S3. Density of various immune cells and their ratio to CD8+ cells as revealed by multiplex immunofluorescence.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Supplementary Figure S2. Changes in peripheral blood cytokines before and after treatment.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Supplementary Figure S2. Changes in peripheral blood cytokines before and after treatment.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Methods S1 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Supplementary Methods S1. Supplementary details of study design, patient enrollment, statistical analysis and sample size calculation.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods S1 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Supplementary Methods S1. Supplementary details of study design, patient enrollment, statistical analysis and sample size calculation.
- 1 July 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF11
Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Purpose: The study was conducted to evaluate porustobart (HBM4003), a novel anti–cytotoxic T lymphocyte–associated protein 4 monoclonal antibody, combined with toripalimab as second-line therapy in advanced hepatocellular carcinoma (HCC). Patients and Methods: This phase I study included two cohorts of patients with advanced HCC: cohort 1 included patients who were anti–PD-1/PD-L1 naïve and had received first-line anti-VEGFR tyrosine kinase inhibitor, and cohort 2 included patients who had failed prior first-line anti–PD-1/PD-L1 and anti-VEGF/VEGFR therapies. Porustobart (0.45 mg/kg) and toripalimab (240 mg) were administered every 21 days. The primary endpoint was the objective response rate (ORR). Results: In total, 16 patients were enrolled in cohort 1 and 12 in cohort 2. In the 26 patients with evaluable efficacy data, the ORR was 23.1% (95% confidence interval, 9.0–43.6). Cohort 1 exhibited an ORR of 40.0%, whereas cohort 2 presented no objective response. The median progression-free survival was 4.2 months, with 5.7 months for cohort 1 and 3.8 months for cohort 2. Biomarker exploration revealed higher abundance of intratumoral regulatory T cells in responders before treatment and a substantial elevation of CD4+Ki67+ and CD8+Ki67+ T cells after treatment. For safety, treatment-emergent adverse events were reported in 27 patients (96.4%), and treatment-related adverse events were reported in 25 patients (89.3%), among whom 13 (46.5%) had grade ≥3 treatment-related adverse events. Serious adverse events were observed in 12 patients (42.9%), and treatment-related serious adverse events were observed in nine patients (32.1%). Conclusions: The combination of porustobart and toripalimab shows promising efficacy as a second-line therapy in anti–PD-1/PD-L1–naïve patients with advanced HCC and a manageable safety profile.
- 1 July 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF11
Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Purpose: The study was conducted to evaluate porustobart (HBM4003), a novel anti–cytotoxic T lymphocyte–associated protein 4 monoclonal antibody, combined with toripalimab as second-line therapy in advanced hepatocellular carcinoma (HCC). Patients and Methods: This phase I study included two cohorts of patients with advanced HCC: cohort 1 included patients who were anti–PD-1/PD-L1 naïve and had received first-line anti-VEGFR tyrosine kinase inhibitor, and cohort 2 included patients who had failed prior first-line anti–PD-1/PD-L1 and anti-VEGF/VEGFR therapies. Porustobart (0.45 mg/kg) and toripalimab (240 mg) were administered every 21 days. The primary endpoint was the objective response rate (ORR). Results: In total, 16 patients were enrolled in cohort 1 and 12 in cohort 2. In the 26 patients with evaluable efficacy data, the ORR was 23.1% (95% confidence interval, 9.0–43.6). Cohort 1 exhibited an ORR of 40.0%, whereas cohort 2 presented no objective response. The median progression-free survival was 4.2 months, with 5.7 months for cohort 1 and 3.8 months for cohort 2. Biomarker exploration revealed higher abundance of intratumoral regulatory T cells in responders before treatment and a substantial elevation of CD4+Ki67+ and CD8+Ki67+ T cells after treatment. For safety, treatment-emergent adverse events were reported in 27 patients (96.4%), and treatment-related adverse events were reported in 25 patients (89.3%), among whom 13 (46.5%) had grade ≥3 treatment-related adverse events. Serious adverse events were observed in 12 patients (42.9%), and treatment-related serious adverse events were observed in nine patients (32.1%). Conclusions: The combination of porustobart and toripalimab shows promising efficacy as a second-line therapy in anti–PD-1/PD-L1–naïve patients with advanced HCC and a manageable safety profile.